Klineo, a Paris, France-based digital health startup, raised €2m in funding.
The round was by BPI France with participation from business angels.
The company intends to use the funds to continue to expand operations, its development efforts to extend the solution to different types of cancer, and its business reach across Europe and US.
Led by CEO Thomas Peyresblanques, and CTO Nicolas Drizard, Klineo provides an AI powered platform that connects doctors and patients of cancer clinical trials. In 2022, the company set up a pilot project at the Gustave Roussy Institute and launched a national platform in triple negative breast cancer in collaboration with the Collectif Triplettes Roses. In 2023, Klineo extended its platform to new cancers (breast, skin, lymphoma, etc.) and aims to cover all cancers by the end of 2024.
Klineo also benefits from the support of various stakeholders such as the BPI, the Pfizer Healthcare Hub , Wilco, Onconumérique, PariSanté Campus and Unicancer.
FinSMEs
29/04/2024